Adrian Stevens
Chief Product Officer, Chemaxon
Developing new science and technologies that aid future drug discovery needs
Adrian looks at some of the trends and challenges in the pharmaceutical industry, and showcases new approaches and ideas that together illustrate potential avenues of exploration within Chemaxon’s portfolio.
Adrian Stevens joined Chemaxon as Chief Product Officer in 2022. Adrian has spent approximately 15 years working in Life Sciences software companies, in product management roles for most of his time.
As a computational chemist at BioFocus PLC, over the course of nearly 10 years, he supported a wide range of areas in therapeutic research, from oncology, metabolic diseases, autoimmune and pain-based medicines. During this time, he specialized in designing small molecule drugs that targeted protein kinases and GPCR proteins, leading to a number of scientific publications and patents.
Adrian has a PhD in Computational Chemistry from the University of Portsmouth.
Talks you might be also interested in
Peter Ertl
Formerly of Novartis
The magic rings: Navigation in the ring chemical space guided by the bioactive rings
Thrasyvoulos Karydis
Deepcure
Is AI in Drug Discovery trapped in the data of the past?
Jessica Lanini
Biomedical Research, Novartis
AI advancing drug discovery research in the pharmaceutical industry and academia